An exclusive Fagron Academy Webinar
Sirolimus (Rapamycin) and Aging
Here is What You'll Learn
Review mechanisms for aging as a whole and age-related diseases broadly
Evaluate data thus far from completed animal and human trials on sirolimus (rapamycin) and aging as well as safety
Briefly review the landscape of pharmaceutical interventions for age-related diseases (ex: metformin)
Discuss planned RAPID clinical trial and why the study was designed in the way that it is
Discuss proposed mechanisms of action of sirolimus (rapamycin) for mitigation of age-related diseases
Dr. Jonathan An
Dr. Jonathan An is an Assistant professor and Assistant Graduate Program Director in Oral Health Sciences at the University of Washington School of Dentistry. He also is an active dentist in Mill Creek, Washington. He completed his dual DDS and PhD degree at the University of Washington, where his PhD was on the basic biological mechanisms of aging in the context of oral biology. His laboratory was one of the first groups to demonstrate the effects of oral rejuvenation by targeting the biological aging process. He is also leading one of the first human clinical trials to evaluate whether targeting an important aging pathway called mTOR can improve periodontitis in older adults, and the only group to have received FDA IND approval to complete this trial. His laboratory works with various animal models, from worms, mice, rats, and non-human primates, to study the impact of aging on oral health and oral biology. In addition to his role at the UW School of Dentistry, he provides care as a dentist in his private practice, merging modern and innovative technology, such as in-house, same-day crowns, clear aligner therapy, and restorative and implant dentistry for his patients.